Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 23, 2015

View Archived Issues

HIV Vaccine Trials Network launches phase I/II trial of prime-boost vaccine

IDRI receives BARDA funding to establish adjuvant hub

E Keppra approved in Japan as monotherapy for partial-onset seizures

Queen Mary University of London and Takeda to develop new gastroenterology therapies

Cerecor acquires kappa opioid receptor antagonist from Eli Lilly

Anti-IL-23 antibody shows clinical effect in Crohn's disease patients

Vichem Chemie Research discloses new FLT3 inhibitors

Anti-MZGP2 antibodies associated with Crohn's disease phenotypes

Actelion Pharmaceuticals patents new lipoxin receptor agonists

Roche patent reports new fusion proteins for Alzheimer's type dementia

New SHIP-2 inhibitors for diabetes designed by University of Toyama

Merck KGaA discloses multiple kinase inhibitors

Novo Nordisk reports positive results from phase II trial of oral semaglutide in type 2 diabetes

Valeant to acquire Salix Pharmaceuticals

Investigators prepare new anti-GARP MAbs

Allergan patents S1P1 receptor ligands

Sosei acquires Heptares Therapeutics

FDA grants orphan drug status to polidocanol for venous malformations

FDA grants priority review to Rapamune sNDA for lymphangioleiomyomatosis

AB-Biotics collaborates with Derbycare to launch AB-Kolicare in China

Shire completes acquisition of NPS Pharmaceuticals

First stem cell-based medicinal product approved in Europe

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 15, 2026.
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...
Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid
BioWorld
Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive...
Fortvita and Innovent patent new anti-TROP2/B7-H4 ADCs
BioWorld Science
Fortvita Biologics Inc. and Innovent Biologics (Suzhou) Co. Ltd. have jointly reported new antibody-drug conjugates (ADCs) comprising a bispecific antibody or...